Transferrin Receptor Antigen-Binding Domains for BBB Drug Transport
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The blood-brain barrier (BBB) restricts the passive transfer of therapeutics to the central nervous system (CNS), limiting the efficacy of recombinant proteins and antibodies, and invasive CNS injections are inefficient due to rapid cerebral spinal fluid export, while systemic high-dose administration causes unintended peripheral effects.
Innovation Solution
Antigen-binding domains, such as those specific to the human transferrin receptor (TfR), are developed to cross the BBB and localize to brain parenchyma after peripheral injection, allowing for targeted delivery of therapeutics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If recombinant proteins and antibody therapeutics are administered systemically, then they can be delivered non-invasively, but they do not cross the BBB efficiently resulting in poor CNS delivery
Solution Approach 1:
The patent uses TfR as an intermediary receptor on the BBB to facilitate therapeutic delivery. The antigen-binding domain binds to TfR, which is then internalized along with the therapeutic payload, allowing non-invasive systemic delivery that overcomes the BBB restriction.
Solution Approach 2:
The patent modifies the therapeutic construct by adding an antigen-binding domain specific for TfR, changing the molecular parameters of the drug to enable recognition and uptake by the BBB receptor, thereby improving penetration efficiency while maintaining non-invasive administration.
2Reliability
If therapeutics are injected directly into the CNS, then sufficient concentration can be achieved in the brain, but the procedure is invasive and efficacy is limited by rapid CSF export
Solution Approach 1:
The TfR receptor serves as a mediator that enables the therapeutic to enter the CNS through the BBB via receptor-mediated endocytosis, achieving effective brain concentration without requiring direct invasive injection into the CNS space.
Solution Approach 2:
The patent replaces the mechanical invasive injection system with a biological transport mechanism where the therapeutic binds to TfR and is transported across the BBB through cellular internalization processes, eliminating the need for direct CNS penetration.
3Reliability
If high dose therapeutic is administered systemically to achieve BBB penetration, then sufficient brain delivery can be achieved, but unintended peripheral effects occur
Solution Approach 1:
The patent creates local quality by directing the therapeutic specifically to the BBB through TfR binding, concentrating the drug's action at the blood-brain barrier interface. This localized mechanism allows effective brain delivery at lower systemic doses, minimizing peripheral harmful effects.
Solution Approach 2:
TfR acts as a selective intermediary that captures the therapeutic at the BBB, preventing widespread peripheral distribution. The receptor-mediated uptake ensures the drug is concentrated at the target site rather than distributed systemically at high doses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antigen-binding domains efficiently deliver therapeutic agents across the BBB, reducing the need for invasive CNS injections and minimizing peripheral side effects by localizing to the brain, thereby enhancing therapeutic efficacy.
Implementation Method 1
These antigen-binding domains can cross the blood brain barrier and can transport other agents (e.g., therapeutically active agents) associated with the antigen-binding domain across the blood brain barrier
Data Source
AI summary
The present disclosure is generally directed to antigen-binding domains that specifically bind to human transferrin receptor (TfR) and their use in transport across the blood brain barrier (BBB).